Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual)			1 Months Ended					3 Months Ended
Commitments and Contingencies (Details Textual)	Feb. 27, 2014 USD ($)	Jul. 24, 2012 USD ($)	Dec. 21, 2015 USD ($)	Apr. 22, 2014 USD ($)	Aug. 28, 2012 USD ($) patients	Jun. 15, 2012 USD ($)	Dec. 31, 2007 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Feb. 16, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2014 USD ($)
Commitments and Contingencies (Textual)
Research recorded fees								$ 3,765,452	$ 4,048,714
Security Deposit				$ 34,733				49,859
Letter of credit				$ 34,733
Sub lease agreement expiration date				Sep. 30, 2016
Cost of lease agreement								16,620
Manufacturing Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost for clinical trials of drug Ac-225-HuM195	$ 5,700,000							2,000,000
Non - refundable institutional fee	$ 600,000
Total project estimated to cost								100,000			$ 100,000
Research and development costs								100,000	2,100,000
Einstein [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost								200,000				$ 200,000
Research and development costs								36,678	55,000
AbbVie Biotherapeutics Corp [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
License fee payment								3,000,000
Milestones payments								$ 7,750,000
Description of royalty payment								The company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.
Royalty of net sales percentage								12.00%
First commercial sale period								12 years 6 months
AbbVie Biotherapeutics Corp [Member] \| After first net sales [Member]
Commitments and Contingencies (Textual)
Milestones payments								$ 1,500,000
AbbVie Biotherapeutics Corp [Member] \| Phase 1 Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones payments		$ 750,000						750,000
Abbott Biotherapeutics Corp [Member] \| After first net sales [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
Net sales in milestones payment								10,000,000
Oak Ridge National Laboratory [Member]
Commitments and Contingencies (Textual)
Research and development costs			$ 900,000					$ 200,000	100,000
Icon Clinical Research [Member]
Commitments and Contingencies (Textual)
Down payment of project estimated cost percentage								12.50%
Down payment for project							$ 200,000	$ 1,900,000
Total project estimated to cost								2,700,000
Research and development costs								$ 200,000	100,000
Fred Hutchinson Cancer Research Center [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Milestones payments						$ 1,000,000
Description of royalty payment								Royalty payments of 2% of net sales will be due to FHCRC.
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )						200,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )						300,000
Research recorded fees								$ 63,000	$ 46,000
Fred Hutchinson Cancer Research Center [Member] \| Maximum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration						23,500,000
Fred Hutchinson Cancer Research Center [Member] \| Minimum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration						$ 13,200,000
University of Texas M.D. Anderson Cancer Center [Member] \| Clinical Trial Agreement [Member]
Commitments and Contingencies (Textual)
Number of Patients \| patients					24
Amount paid to each patient after Completing clinical trial					$ 500,000
Start-up fee for clinical trial					$ 33,946
Start-up due cost paid date					Dec. 31, 2015
Non - refundable institutional fee					$ 14,500
Medpace Inc [Member] \| CRO Agreement [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost										$ 6,600,000
Research and development costs								$ 900,000